This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
startups raised half a billion dollars apiece, and another eight raised $100 million or more, with industries from cybersecurity to biotech to AI represented. tied) Fingercheck , $115M, human resources: Small business payroll and human resource software company Fingercheck raised a $115 million growth investment led by Edison Partners.
Use discount code TCPLUSROUNDUP to save 20% off a one- or two-year subscription. “We A prep checklist for startups about to undergo technical duediligence. Code quality. Code, network and information security. A prep checklist for startups about to undergo technical duediligence. Budding Biotech.
JP Morgan’s announcement comes at a time when, in the words of B Capital general partner and head of healthcare Robert Mittendorff M.D, “public market biotechs are dramatically down as interest rates rise and the focus on near-term development outweighs the promise of longer-term results and approvals.”
Given this success, many biotech companies are looking to move on to the next phase of their organizational growth — which may mean an initial public offering. As optimism grows, market conditions may stabilize in 2025 — particularly in the wake of the recent interest rate cuts — and more biotech companies may consider offerings.
Medical and biotech had a strong showing at Y Combinator’s latest demo day , with nearly a dozen companies in the space catching my eye. These tools can essentially “code” a molecule so that it reliably sticks to a specific substance or cell type, which allows a variety of follow-up actions to be taken.
Lambda , $480M, artificial intelligence: Lambda, which offers cloud computing services and hardware for training artificial intelligence software, raised a $480 million Series D co-led by Andra Capital and SGW. Eikon Therapeutics , $351M, biotech: Eikon Therapeutics raised one of the biggest biotech rounds thus far in 2025.
national security review on UAE-based G42 ‘s minority investment in the AI chipmaker. In 2002, prior to founding SymphonyAI, Wadhwani founded Symphony Technology Group , a private equity firm investing in software and technology-enabled services companies. It filed to go public openly in September. That made sense.
Venture money wasnt concentrated in just one sector, as VCs invested in everything from artificial intelligence to biotech to energy. tied) Retro Biosciences , $1B, biotech: AI can do a lot startup Retro Biosciences thinks it can even help us live longer. billion valuation. In November 2021, Helion closed a $500 million Series E.
Full TechCrunch+ articles are only available to members Use discount code TCPLUSROUNDUP to save 20% off a one- or two-year subscription Before Silicon Valley Bank crashed, I asked seven VCs about the startups they’re interested in backing right now, how they prefer to be approached and whether they could share any tips for first-time founders. “The
That increase was due in large part to U.S. AI led The 2024 surge in new unicorns was led by the AI sector, which included companies focused on foundation models, AI infrastructure and coding. Healthcare and biotech was the third-highest sector for new unicorns with nine companies. US gained Of the new 2024 unicorns, 65 are U.S.-based
Latigo Biotherapeutics , $150M, biotech: Many patients shy away from taking opioids while many doctors are reluctant to prescribe the painkillers. Curevo , $110M, biotech: Seattle-based Curevo, a clinical-stage biotechnology company developing vaccinations for infectious disease, closed a $110 million Series B led by new investor Medicxi.
Every branch of science is increasingly reliant on big data sets and analysis, which means a growing confusion of formats and platforms — more than inconvenient, this can hinder the process of peer review and replication of research. That, at least, is the pitch Code Ocean offers for its platform and “Compute Capsules.”
Normally, a CCO develops ideas about what the market needs and communicates them to a design team, which produces sketches to then be reviewed by the CCO. Helping software developers write and test code Similarly in tech, companies are currently open about some of their use cases, but protective of others.
Not only does the software help sort and analyze ultrasound images to help doctors diagnose cardiovascular disease, but it also streamlines the workflow by generating patient reports for doctors that can then be added to a patient’s health record. AI is ready to take on a massive healthcare challenge. ” said Hewitt.
Deep tech, medtech/biotech, climate tech, and crypto and blockchain are all areas that investors say they’re either actively investing in or watching for signs of scale. Now, certain industries are emerging as potential areas where New Zealand can win in the tech space. New Zealanders make really good founders.
Biotech took center stage, notching three of the top four rounds. Obsidian Therapeutics , $161M, biotech: It was another big week for biotech startups raising huge sums of cash. It also included a $50 million investment from advertising software firm AppLovin. This week, Obsidian Therapeutics leads the way.
According to research, 85% of African SMBs have zero access to financing, and e ach day, African SMBs have billions locked up in receivables due to long payment cycles. ” All the companies from Y Combinator’s W20 Demo Day, Part IV: Healthcare, Biotech, Fintech and Nonprofits.
France could become a leading market when it comes to sustainability-focused and impact startups due to local and European regulation, innovation and talent looking for opportunities in this ecosystem. But impact companies could still benefit from new processes, better network effects and more ambition in general.
There are any number of seed rounds that cross our desks every day, a never-ending march of enterprise software, consumer apps, games, hardware, biotech and sometimes even a space startup. But amid the regular flow of funding news, it’s still rare to come across a company raising money to take on addiction with software.
The idea of starting Healthie , a software company meant to help healthcare companies and startups handle back-office operations, came to founder Erica Jain after witnessing her parents struggle with weight loss but lack of access to a comprehensive care team. million and will use this round’s funds to continue developing their software.
For perspective, we charted investment totals, color-coded by stage, for the past 11 quarters below. While the IPO market wasn’t especially active, we did see a handful of public offerings, predominantly in the biotech sector. It should be noted that Q2’s high early-stage tally was largely due to a single $6.4
Automated driving company Wayve , data preparation company Scale AI and AI biotech company Xaira Therapeutics each raised billion-dollar rounds. Healthcare and biotech was the second-largest sector, raising $17 billion. Hardware companies — in large part due to AI infrastructure and semiconductor fundings — raised $11 billion.
Research on psychedelics was stalled for decades due to DEA scheduling, but capabilities in the fields of pharmacology and medicinal chemistry advanced significantly during this “dark age.” Cannabinoid biotech offers some glimmers of what could occur in psychedelics, with Jazz Pharma acquiring GW Pharma for $7.2
Other investors felt that a broader range of industries, like fintech and biotech, would eventually produce the biggest companies in the country. Save 25% off a one- or two-year Extra Crunch membership by entering this discount code: THANKYOUISRAEL. Zoomin Software. Rafi Carmeli , partner, Viola Growth. Yes in many areas.
Before you can even start to disentangle someone’s genetic code, you have to start with a sample. However, as the authors of a 2020 review paper on the electrowetting industry note, the instrument was “discontinued for undisclosed reasons” in 2017. The fourth company is a biotech firm interested in synthetic biology.
Meatable has a long road ahead of it, because, as Gates acknowledged in his interview with MIT Technology Review (ed. Strategic investors like DSM, one of the largest food biotech companies in Europe should help. Use code “TCARTICLE” at checkout to get 20 percent off tickets right here.
Then, late last year, Cruise suspended its self-driving taxi program across the country after losing its permit to operate in San Francisco due to an incident with a pedestrian. Formation Bio , $372M, biotech: Formation Bio, an AI-enhanced pharma company, raised a $372 million Series D led by a16z. billion, per Crunchbase.
These near-invisible bits of code are typically embedded in web pages to share information about users’ activity, often for analytics. Cerebral said these trackers inadvertently collected sensitive user data since it began operating in October 2019. In its disclosure to the U.S.
The world’s labs are under pressure to do more tests and process more materials, not just due to COVID but from the growing biotech and drug development sectors — and automation is the sure path forwards. To that end Automata has been investing in the software to manage and administer its labware and robots.
He hopes to use data from a massive biobank effort, first planned under the Obama administration and now known as All of Us, to map the genetic code of one million people. He was cofounder of a company called Arivale, which analyzed the genes of some 5,000 people, but closed in 2019 due to financial problems.
He puts his tally for the number of applications he’s reviewed in the “tens of thousands.” For a SaaS startup, that might mean a programmer who’s proven they can build and ship; for a biotech company, perhaps it’s less about coding and more about field expertise.
Despite advances in software to help model these compounds and molecules, there are still challenges in fully understanding their shapes through a two-dimensional computer screen. San Diego-based startup Nanome uses virtual reality to solve that problem. Nanome helps scientists get on the same page quicker,” he wrote in an email.
Then, this year, the Great Resignation became the Great Reset, as employers fired large percentages of their staff due to changing macroeconomic conditions. 6 investors discuss why AI is more than just a buzzword in biotech. Gift Guide: More than 20 STEM gift ideas to inspire kids to code. 7 great gifts for smart home smarties.
Once samples are scanned in the lab, they could be reviewed by hematologists working from anywhere. For instance, some papers argue, the manual review of samples doesn’t often add much to doctors’ diagnostic dataset. Think of this like support software that helps a hematologist distinguish between cell types.).
InstaDeep utilizes advanced machine learning techniques, including deep reinforcement learning in applications within an enterprise environment that cuts across various industries such as biotech, transportation, electronics manufacturing and logistics.
The Silicon Valley-based firm, active in software, biotech and cleantech, participated in 26 deals last quarter. Next is Coatue, mostly due to its role as lead investor in CoreWeave ’s $1.1 billion Series C. In third place is Accel, which led Scale AI ’s $1 billion Series F.
Those with disclosed investments include a number bringing AI-enabled tools to sectors like legal tech, recruiting, code development and medical recordkeeping. San Francisco is experiencing a resurgence due to AI , which is borne out by Crunchbase data. This allows for front loading duediligence.
The investment scene is described variously as focusing on software, clean tech, life sciences, biotech, organoids, 3D bioprinting, AI and VR/AR. We see an increase in startups coming to the city, due to livability in the lovely city and the facilities for flex working. Focus on software and clean tech. Channable, Tover.
For software companies acquired for a billion dollars or more, private equity acquired the majority this year to date. With all the venture funding in biotech , it is no surprise that one of the largest deals was Merck ’s acquisition of New York-based eye disease therapy company Eyebiotech.
It also participated in the gigantic $1 billion raise by Xaira Therapeutics , a startup at the intersection of AI and biotech. The 6-month-old startup has developed an artificial intelligence–powered coding assistant called Devin. It does not include incubators or accelerators due to the fluctuations their investment numbers can have.
A number of biotechs also carried out IPOs. Buyer, however, believes debut plans are getting delayed largely because many pre-IPO companies, particularly in enterprise software, are growing at slower rates than was typical during the bull market. But most weeks, the market has been uncharacteristically quiet.
The company’s printers and software can print more than just swabs, but the first product the company has focused on since 2020 is the InstaSwab — a 3D-printed swab used in COVID-19 tests. . Case in point: one systematic review of 34 studies found estimates ranging from a 2% false negative rate to 29%. Image: OPT Industries.
” Bastani points out that they began the company by focusing this approach to patient education and communication on HIV, and demonstrated that using their software led to patients being 7.4 Apple and Google release sample code, UI and detailed policies for COVID-19 exposure-notification apps.
Use discount code SCOTLANDSURVEY to save 25% off an annual or two-year Extra Crunch membership. Experiencing influx of new talent due to COVID-19. Weak in deep tech discovery, especially in biotech/therapeutics. This offer is only available to readers in the UK Europe and expires on June 30, 2021. Par Equity is leading the way.
We organize all of the trending information in your field so you don't have to. Join 49,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content